HALO AP Dx

Looking Back: Reviewing 2025 at Indica Labs

As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.

Looking Back: Reviewing 2025 at Indica Labs Read More »

The rapid global adoption of HALO AP® prompted immediate localization of the platform in Chinese, Danish, Dutch, American and British English, Finnish, French, German, Greek, Italian, Norwegian, Japanese, Portuguese, Russian, Spanish, Slovakian, and Swedish. Shown here are all 17 languages represented as each country's flags.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets

Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »

Indica Labs, HALO AP Dx, FDA 510(k)-cleared digital pathology platform displayed with the Aperio GT 450 DX Scanner for in vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems

ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems Read More »

Looking Back: Reviewing 2024 at Indica Labs

As 2024 draws to a close, we at Indica Labs would like to thank the customers and collaborators who helped fill 2024 with exciting discoveries, events, and partnerships. It is a great honor to have played a part in customers’ contributions to scientific fields ranging from immuno-oncology to infectious disease, immunology, neuroscience, and metabolism.

Looking Back: Reviewing 2024 at Indica Labs Read More »

Enhancing Patient Care with Seamless Clinical Collaboration: Streamlining Tumor Boards and MDTs with the Tumor Board Functionality of HALO AP® and HALO AP Dx

With the HALO AP platforms and their dedicated Tumor Board functionalities, pathologists can enhance multidisciplinary communication and improve treatment planning.

Enhancing Patient Care with Seamless Clinical Collaboration: Streamlining Tumor Boards and MDTs with the Tumor Board Functionality of HALO AP® and HALO AP Dx Read More »

Indica Labs Expands Availability of HALO Digital Pathology Solutions in Asia Pacific Region Including CE-IVDR Marked HALO AP® Platform

Albuquerque, NM – 2 July 2024 – Indica Labs today announces the expansion of their reseller network in the Asia Pacific (APAC) region.

Indica Labs Expands Availability of HALO Digital Pathology Solutions in Asia Pacific Region Including CE-IVDR Marked HALO AP® Platform Read More »

Scroll to Top